These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 34506327

  • 1. A review of ophthalmic manifestations of inflammatory bowel disease and associated treatments.
    Janardhana P, Al-Kadhi S.
    Curr Opin Ophthalmol; 2021 Nov 01; 32(6):549-554. PubMed ID: 34506327
    [Abstract] [Full Text] [Related]

  • 2. Ophthalmic manifestations in patients with inflammatory bowel disease: A review.
    Troncoso LL, Biancardi AL, de Moraes HV, Zaltman C.
    World J Gastroenterol; 2017 Aug 28; 23(32):5836-5848. PubMed ID: 28932076
    [Abstract] [Full Text] [Related]

  • 3. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
    Rawla P, Sunkara T, Raj JP.
    J Inflamm Res; 2018 Aug 28; 11():215-226. PubMed ID: 29844695
    [Abstract] [Full Text] [Related]

  • 4. Ocular Manifestations of Inflammatory Bowel Disease.
    Shah J, Shah A, Hassman L, Gutierrez A.
    Inflamm Bowel Dis; 2021 Oct 20; 27(11):1832-1838. PubMed ID: 33501989
    [Abstract] [Full Text] [Related]

  • 5. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
    Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RAR, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR, Swiss IBD Cohort Study Group.
    J Pediatr Gastroenterol Nutr; 2017 Aug 20; 65(2):200-206. PubMed ID: 27801751
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prevalence and clinical features of chronic uveitis in pediatric inflammatory bowel diseases: A nationwide study.
    Maniscalco V, Scarallo L, Aloi M, Alvisi P, Norsa L, Zuin G, Simonini G, Lionetti P.
    J Pediatr Gastroenterol Nutr; 2024 Jun 20; 78(6):1305-1309. PubMed ID: 38594804
    [Abstract] [Full Text] [Related]

  • 8. Expanded table: Some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul 10; 65(1680):e115-e119. PubMed ID: 37418332
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A, GETAID OBSERV-IBD study group.
    Aliment Pharmacol Ther; 2018 Feb 10; 47(4):485-493. PubMed ID: 29250803
    [Abstract] [Full Text] [Related]

  • 11. Treatment of extraintestinal manifestations in inflammatory bowel disease.
    Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S.
    Digestion; 2012 Feb 10; 86 Suppl 1():28-35. PubMed ID: 23051724
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The prevalence of ocular involvement in patients with inflammatory bowel disease.
    Yilmaz S, Aydemir E, Maden A, Unsal B.
    Int J Colorectal Dis; 2007 Sep 10; 22(9):1027-30. PubMed ID: 17262200
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Asymptomatic uveitis in children with chronic inflammatory bowel diseases.
    Hofley P, Roarty J, McGinnity G, Griffiths AM, Marcon M, Kraft S, Sherman P.
    J Pediatr Gastroenterol Nutr; 1993 Nov 10; 17(4):397-400. PubMed ID: 8145095
    [Abstract] [Full Text] [Related]

  • 16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 17. Uveitis in pediatric inflammatory bowel disease.
    Yu K, Davidson S, Binenbaum G.
    J AAPOS; 2023 Jun 14; 27(3):153-155. PubMed ID: 37201627
    [Abstract] [Full Text] [Related]

  • 18. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M.
    Acta Med Croatica; 2013 Apr 14; 67(2):195-201. PubMed ID: 24471303
    [Abstract] [Full Text] [Related]

  • 19. Biologics for extraintestinal manifestations of IBD.
    Vavricka SR, Scharl M, Gubler M, Rogler G.
    Curr Drug Targets; 2014 Apr 14; 15(11):1064-73. PubMed ID: 25198785
    [Abstract] [Full Text] [Related]

  • 20. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul 02; 60(1550):107-114. PubMed ID: 30036352
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.